Opendata, web and dolomites

ONCOCHECK

A simple blood test for prognosis and monitoring of patients undergoing cancer therapy.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "ONCOCHECK" data sheet

The following table provides information about the project.

Coordinator
LIFE LENGTH SL 

Organization address
address: CALLE MIGUEL ANGEL 11 2 PLANTA
city: MADRID
postcode: 28010
website: www.lifelength.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.oncocheck.eu/
 Total cost 3˙109˙948 €
 EC max contribution 3˙109˙948 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2018-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LIFE LENGTH SL ES (MADRID) coordinator 3˙109˙948.00

Map

 Project objective

The objective of the ONCOCHECK project is to bring to the healthcare market a unique solution for cancer prognosis and monitoring which is a simple and inexpensive (<€200/test) blood test that will allow oncologists the prediction and evaluation of disease progression (monitoring) in patients affected by the great majority of cancers, with no distinction between haematological or solid tumors. The ONCOCHECK test is based on the determination of telomere length in peripheral blood, which is a blood cell marker that has been identified in the majority of cancers. The great advantage of the ONCOCHECK tests over any competing blood tests based on cancer tumor markers is that ONCOCHECK will serve for monitoring virtually all types of cancer, while competing tumor marker based solutions are useful only for a specific cancer/tumor. Therefore, Life Length´s test will offer a universal solution for cancer monitoring, with no competitors offering a similar approach. Considering the more than 35 million of people affected by cancer all over the world and that ONCOCHECK will serve for monitoring all cancer types, the business opportunity seems unquestionable. Through the ONCOCHECK project, we seek positioning our company as a leading player in the Advanced Next Generation Cancer Diagnostic Market, which was already estimated globally to generate €7.1 billion in sales in 2015 and is forecast to exceed €13.1 billion by 2020. The main market drivers are the development of less invasive and less costly tools that can contribute to a more efficient, more frequent and sustainable management of cancer. In line with this, the ONCOCHECK project will offer oncologist a cost effective solution to the current challenges in regular cancer monitoring and management.

 Deliverables

List of deliverables.
ONCOCHECK webpage. Websites, patent fillings, videos etc. 2019-07-18 22:20:30

Take a look to the deliverables list in detail:  detailed list of ONCOCHECK deliverables.

 Publications

year authors and title journal last update
List of publications.
2017 J.A García-Marco1, A. Alegre2, P Baltasar3, J Loscertales2, J.A. Hernández Rivas4, R Martínez5, P Sánchez Godoy6, J. de la Serna7, J.A. García-Vela8, Laura Esteban9, Nuria de Pedro10, Irene García10, Lissette Otero10, Juan Estrada10, Jorge García10, María Diez10, Rut González10, Beatriz García10, Rafael Higuera11, Enrique Segovia11, Luis Fernández11 and Pilar Najarro9. On behalf of GMCLL
Estudio de validación clínica de las variables a los telómeros como biomarcadores pronóstico en LLC
published pages: PC-143 Abstract,, ISSN: , DOI:
Published during the SEHH annual congress (http://www.sehhseth.es/es/) 2019-07-18
2017 Pilar Najarro (Life Length Scientific Director & COO)
Outrunning ageing and cancer
published pages: 180-181, ISSN: , DOI:
Horizon 2020 Projects: Portal 2019-07-18
2017 N. De Pedro, J.C. Estrada , M. Chiesa, M. Diez , I. Garcia , R. Gonzalez , B. Garcia , J. Garcıa , L. Esteban , L. Otero , P. Najarro
Telomere associated variables and their potential in CLL prognosis
published pages: (Abstract 98P, p, ISSN: , DOI:
ESMO Annals of Oncology (Abstract Book) Abstract Book of the 42nd ESMO 2019-07-18

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCOCHECK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ONCOCHECK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More